India, Uzbekistan Discuss Ways To Ensure Quality, Safety In Pharma Sector

New Delhi:  A delegation from Uzbekistan met officials from India’s Central Drugs Standard Control Organisation and discussed areas of collaboration, including the development of a pharmacovigilance system and reducing adverse effects of pharmaceutical products, officials said on Wednesday.

The delegation led by Alisher Temirov, Director of the Center for Pharmaceutical Products Safety, Uzbekistan had detailed discussions with Ranga Chandrashekar, Joint Drugs Controller of India’s regulatory body for drug control, regarding the quality and safety in the pharma sector, they added.

“Several important issues were discussed during the meeting, including the development of a pharmacovigilance system, reducing the adverse effects of pharmaceutical products, and identifying ways to prevent potential risks. It was emphasised that strengthening international cooperation in this area is crucial for ensuring public health,” an official statement said.

Temirov stressed the importance of developing effective mechanisms to prevent the entry of low-quality and counterfeit drugs into Uzbekistan’s pharmaceutical market.

“He emphasized the need for specific measures and close cooperation in verifying the authenticity of regulatory documents. The Indian officials expressed readiness to further improve internal control mechanisms and enhance cooperation with the Center to prevent the entry of pharmaceutical products that have not passed quality control into the Uzbek market,” the statement added.

The meeting was held during the 19th International Conference of Drug Regulatory Authorities (ICDRA).

Related Posts

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?